 Kintara Therapeutics Inc NASDAQ: KTRA has enrolled the final patient in the recurrent arm of its ongoing Phase 2 study evaluating VAL-083 for glioblastoma multiforme, the most aggressive form of brain cancer. The studys recurrent arm in 83 pre-treated patients with temozolomide TMZ is being conducted at the MD Anderson Cancer Center. 